Form 8-K - Current report:
SEC Accession No. 0001655759-24-000043
Filing Date
2024-04-11
Accepted
2024-04-11 07:03:27
Documents
17
Period of Report
2024-04-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K arvn-20240410.htm   iXBRL 8-K 38112
2 EX-99.1 pressrelease_arvinasnvsa.htm EX-99.1 8948
6 pressrelease_arvinasnvsa001.jpg GRAPHIC 241617
7 pressrelease_arvinasnvsa002.jpg GRAPHIC 271827
8 pressrelease_arvinasnvsa003.jpg GRAPHIC 30647
  Complete submission text file 0001655759-24-000043.txt   932696

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT arvn-20240410.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT arvn-20240410_lab.xml EX-101.LAB 23451
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT arvn-20240410_pre.xml EX-101.PRE 13581
20 EXTRACTED XBRL INSTANCE DOCUMENT arvn-20240410_htm.xml XML 2816
Mailing Address 395 WINCHESTER AVE 5 SCIENCE PARK NEW HAVEN CT 06511
Business Address 395 WINCHESTER AVE 5 SCIENCE PARK NEW HAVEN CT 06511 203-535-1456
ARVINAS, INC. (Filer) CIK: 0001655759 (see all company filings)

EIN.: 472566120 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38672 | Film No.: 24837111
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)